Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2020 1
2021 7
2022 5
2023 2
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Unknown field was ignored: [Grants and Funding]
Page 1
Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials.
Mortby ME, Adler L, Agüera-Ortiz L, Bateman DR, Brodaty H, Cantillon M, Geda YE, Ismail Z, Lanctôt KL, Marshall GA, Padala PR, Politis A, Rosenberg PB, Siarkos K, Sultzer DL, Theleritis C; ISTAART NPS PIA. Mortby ME, et al. Am J Geriatr Psychiatry. 2022 Feb;30(2):119-147. doi: 10.1016/j.jagp.2021.06.016. Epub 2021 Jul 1. Am J Geriatr Psychiatry. 2022. PMID: 34315645 Free article. Review.
A better understanding of the subdomains and biological mechanisms of apathy will advance apathy as a treatment target for clinical trials....
A better understanding of the subdomains and biological mechanisms of apathy will advance apathy as a treatment target for clinical …
Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease.
Mielke MM, Anderson M, Ashford JW, Jeromin A, Lin PJ, Rosen A, Tyrone J, Vandevrede L, Willis DR, Hansson O, Khachaturian AS, Schindler SE, Weiss J, Batrla R, Bozeat S, Dwyer JR, Holzapfel D, Jones DR, Murray JF, Partrick KA, Scholler E, Vradenburg G, Young D, Braunstein JB, Burnham SC, de Oliveira FF, Hu YH, Mattke S, Merali Z, Monane M, Sabbagh MN, Shobin E, Weiner M, Udeh-Momoh CT. Mielke MM, et al. Alzheimers Dement. 2024 Nov;20(11):8216-8224. doi: 10.1002/alz.14184. Epub 2024 Oct 1. Alzheimers Dement. 2024. PMID: 39351838 Free PMC article. Review.
Blood-based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. ...Their unique scalability addresses the anticipated surge in demand for biomarker testing with the emergence of disease …
Blood-based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support a …
[Alzheimer's Therapeutic Research Institute].
Shimada H, Kato Y, Fujii H, Mori H. Shimada H, et al. Brain Nerve. 2017 Jul;69(7):856-861. doi: 10.11477/mf.1416200831. Brain Nerve. 2017. PMID: 28740001 Review. Japanese.
The Alzheimer's Therapeutic Research Institute (ATRI) was established in 2015 after ATRI director, Paul Aisen, and his fellow experts in therapeutic interventions for Alzheimer's disease (AD) moved from the Alzheimer's Di …
The Alzheimer's Therapeutic Research Institute (ATRI) was established in 2015 after ATRI director, Paul Aisen, and his …
Expectations and clinical meaningfulness of randomized controlled trials.
Petersen RC, Aisen PS, Andrews JS, Atri A, Matthews BR, Rentz DM, Siemers ER, Weber CJ, Carrillo MC. Petersen RC, et al. Alzheimers Dement. 2023 Jun;19(6):2730-2736. doi: 10.1002/alz.12959. Epub 2023 Feb 7. Alzheimers Dement. 2023. PMID: 36748826 Free PMC article.
Alzheimer's disease (AD) clinical trials are designed and powered to detect the impact of a therapeutic intervention, and there has been considerable discussion on what constitutes a clinically meaningful change in those receiving treatment vers …
Alzheimer's disease (AD) clinical trials are designed and powered to detect the impact of a therapeutic i …
Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease.
Mielke MM, Anderson M, Ashford JW, Jeromin A, Lin PJ, Rosen A, Tyrone J, VandeVrede L, Willis D, Hansson O, Khachaturian AS, Schindler SE, Weiss J, Batrla R, Bozeat S, Dwyer JR, Holzapfel D, Jones DR, Murray JF, Partrick KA, Scholler E, Vradenburg G, Young D, Braunstein JB, Burnham SC, de Oliveira FF, Hu YH, Mattke S, Merali Z, Monane M, Sabbagh MN, Shobin E, Weiner MW, Udeh-Momoh CT. Mielke MM, et al. Alzheimers Dement. 2024 Nov;20(11):8209-8215. doi: 10.1002/alz.14150. Epub 2024 Oct 6. Alzheimers Dement. 2024. PMID: 39369283 Free PMC article.
Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. ...However, several critical considerations, such as the lack of consistent guidelines for assessing cognition, limited und …
Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequa …
Pathways to personalized medicine-Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease.
Arnold SE, Hyman BT, Betensky RA, Dodge HH. Arnold SE, et al. Alzheimers Dement. 2024 Oct;20(10):7384-7394. doi: 10.1002/alz.14063. Epub 2024 Sep 6. Alzheimers Dement. 2024. PMID: 39240044 Free PMC article. Review.
Biological and clinical heterogeneity is a major challenge in research for developing new treatments for Alzheimer's disease (AD). AD may be defined by its amyloid beta and tau pathologies, but we recognize that mixed pathologies are common, and that diverse …
Biological and clinical heterogeneity is a major challenge in research for developing new treatments for Alzheimer's diseas …
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.
Scott GD, Arnold MR, Beach TG, Gibbons CH, Kanthasamy AG, Lebovitz RM, Lemstra AW, Shaw LM, Teunissen CE, Zetterberg H, Taylor AS, Graham TC, Boeve BF, Gomperts SN, Graff-Radford NR, Moussa C, Poston KL, Rosenthal LS, Sabbagh MN, Walsh RR, Weber MT, Armstrong MJ, Bang JA, Bozoki AC, Domoto-Reilly K, Duda JE, Fleisher JE, Galasko DR, Galvin JE, Goldman JG, Holden SK, Honig LS, Huddleston DE, Leverenz JB, Litvan I, Manning CA, Marder KS, Pantelyat AY, Pelak VS, Scharre DW, Sha SJ, Shill HA, Mari Z, Quinn JF, Irwin DJ. Scott GD, et al. Front Neurol. 2022 Jan 31;12:805135. doi: 10.3389/fneur.2021.805135. eCollection 2021. Front Neurol. 2022. PMID: 35173668 Free PMC article. Review.
The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLBs) and Parkinson's disease dement …
The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to presen …
Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report.
Jicha GA, Abner EL, Arnold SE, Carrillo MC, Dodge HH, Edland SD, Fargo KN, Feldman HH, Goldstein LB, Hendrix J, Peters R, Robillard JM, Schneider LS, Titiner JR, Weber CJ; Clinical Trial Advancement & Methodology Professional Interest Area of the International Society to Advance Alzheimer's Research and Treatment (ISTAART). Jicha GA, et al. Alzheimers Dement. 2022 Jun;18(6):1109-1118. doi: 10.1002/alz.12461. Epub 2021 Sep 29. Alzheimers Dement. 2022. PMID: 34590417 Free PMC article.
BACKGROUND: Consensus guidance for the development and identification of high-quality Alzheimer's disease clinical trials is needed for protocol development and conduct of clinical trials. ...CONCLUSIONS: This consensus guidance sh …
BACKGROUND: Consensus guidance for the development and identification of high-quality Alzheimer's disease clinical …
ARMADA: Assessing reliable measurement in Alzheimer's disease and cognitive aging project methods.
Weintraub S, Karpouzian-Rogers T, Peipert JD, Nowinski C, Slotkin J, Wortman K, Ho E, Rogalski E, Carlsson C, Giordani B, Goldstein F, Lucas J, Manly JJ, Rentz D, Salmon D, Snitz B, Dodge HH, Riley M, Eldes F, Ustsinovich V, Gershon R. Weintraub S, et al. Alzheimers Dement. 2022 Aug;18(8):1449-1460. doi: 10.1002/alz.12497. Epub 2021 Nov 17. Alzheimers Dement. 2022. PMID: 34786833 Free PMC article.
INTRODUCTION: Early detection of cognitive decline in older adults is a public health priority. Advancing Reliable Measurement in Alzheimer's Disease and Cognitive Aging (ARMADA), a multisite study, is validating cognition, emotion, motor, and sensory …
INTRODUCTION: Early detection of cognitive decline in older adults is a public health priority. Advancing Reliable Measurement in Alzheim …
Diagnostic criteria for apathy in neurocognitive disorders.
Miller DS, Robert P, Ereshefsky L, Adler L, Bateman D, Cummings J, DeKosky ST, Fischer CE, Husain M, Ismail Z, Jaeger J, Lerner AJ, Li A, Lyketsos CG, Manera V, Mintzer J, Moebius HJ, Mortby M, Meulien D, Pollentier S, Porsteinsson A, Rasmussen J, Rosenberg PB, Ruthirakuhan MT, Sano M, Zucchero Sarracini C, Lanctôt KL. Miller DS, et al. Alzheimers Dement. 2021 Dec;17(12):1892-1904. doi: 10.1002/alz.12358. Epub 2021 May 5. Alzheimers Dement. 2021. PMID: 33949763 Free PMC article.
METHODS: The International Society for CNS Clinical Trials Methodology Apathy Work Group convened an expert group and sought input from academia, health-care, industry, and regulatory bodies. ...
METHODS: The International Society for CNS Clinical Trials Methodology Apathy Work Group convened an expert group and sought i …
17 results